BGB-DXP593 Completed Phase 1 Trials for Coronavirus Disease 2019 (COVID‑19) Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science1
clinicaltrials.gov IdentifierTitleDrugs
NCT04532294Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants